News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Vectura Group plc Results Beat View; Will Up R&D by 10%; Seeks New US Licensee For VR315
June 7, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Dow Jones -- U.K. drug company Vectura Group PLC (VEC.LN) Monday said it is eager to sign up a new partner to help bring generic asthma medicine VR315 to market in the U.S.
Twitter
LinkedIn
Facebook
Email
Print